4D Molecular Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
4D Molecular Therapeutics, Inc. carries a market capitalization of 712.10M, placing it among publicly traded companies globally. Its enterprise value stands at 412.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 712.10M |
| Enterprise Value | 412.23M |
Share Statistics
4D Molecular Therapeutics, Inc. currently has 55.21M shares outstanding.
| Shares Outstanding | 55.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9.37, and the price-to-book ratio stands at 1.80.
| PE Ratio | N/A |
| PS Ratio | 9.37 |
| PB Ratio | 1.80 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | -5.52 |
| P/OCF Ratio | -5.52 |
Enterprise Valuation
| EV / Sales | 4.48 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
4D Molecular Therapeutics, Inc. maintains a current ratio of 8.03, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.03 |
| Quick Ratio | 7.68 |
| Debt / Equity | 9.62 |
| Debt / EBITDA | -0.21 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -43.25 |
| Return on Assets (ROA) | -37.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
4D Molecular Therapeutics, Inc.'s stock has gained approximately 14.37445% over the past 52 weeks. The 50-day moving average sits at 13.94, while the 200-day moving average is 10.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 14.37445% |
| 50-Day Moving Average | 13.94 |
| 200-Day Moving Average | 10.67 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, 4D Molecular Therapeutics, Inc. generated 92.01M in revenue and converted that into -179.17M in net income, yielding earnings per share of -2.76. EBITDA reached -188.99M, while operating income came in at -197.11M.
| Revenue | 92.01M |
| Gross Profit | N/A |
| Operating Income | -197.11M |
| Pretax Income | -179.17M |
| Net Income | -179.17M |
| EBITDA | -188.99M |
| EBIT | -197.11M |
| Earnings Per Share (EPS) | -2.76 |
Balance Sheet
4D Molecular Therapeutics, Inc. holds 361.33M in cash and equivalents against 39.22M in total debt, resulting in a net debt position of -50.78M. Total book value stands at 407.66M, with working capital of 335.28M providing operational flexibility.
| Cash & Cash Equivalents | 361.33M |
| Total Debt | 39.22M |
| Net Debt | -50.78M |
| Equity (Book Value) | 407.66M |
| Book Value Per Share | 7.38 |
| Working Capital | 335.28M |
Cash Flow
4D Molecular Therapeutics, Inc. produced -156.07M in operating cash flow over the past twelve months. After subtracting 161,000.00 in capital expenditures, free cash flow totaled -155.91M - equivalent to -2.41 per share.
| Operating Cash Flow | -156.07M |
| Capital Expenditures | 161,000.00 |
| Free Cash Flow | -155.91M |
| FCF Per Share | -2.41 |
Margins
4D Molecular Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -214.24 and net profit margin of -194.74 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -214.24 |
| Pretax Margin | -194.74 |
| Profit Margin | -194.74 |
| EBITDA Margin | -205.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -22.59 |
| FCF Yield | -18.12 |
Scores
4D Molecular Therapeutics, Inc. posts an Altman Z-Score of 2.43, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.43 |